NCT01694147

Brief Summary

To investigate the possible mechanisms of pulmonary and systemic permeability change including cytokine, extravascular lung water index (EVLWI), and oxygenation parameters in patients with sepsis related acute lung injury (ALI)/acute respiratory distress syndrome (ARDS).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2011

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

September 23, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 27, 2012

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2017

Completed
Last Updated

July 28, 2015

Status Verified

September 1, 2012

Enrollment Period

5.4 years

First QC Date

September 23, 2012

Last Update Submit

July 27, 2015

Conditions

Keywords

relationshipendothelial injuryvascular permeabilitysevere sepsis related ALI/ARDS

Outcome Measures

Primary Outcomes (1)

  • vascular permeability of sepsis related ALI/ARDS

    vascular permeability (day 1 and 3 EVLWI, lung permeability, 24hr fluid balance, microalbuminuria, DAMPs/RAGE, Ang-1, 2 and TIE-2 level, will be detected in the blood sampling) and sepsis-induced ALI/ARDS.

    3 days

Secondary Outcomes (1)

  • relationship between endothelial injury and vascular permeability.

    3 days

Study Arms (1)

patients with sepsis related ALI/ARDS.

Consecutive septic patients with ALI/ARDS in medical intensive care units (ICUs) will be enrolled. EVLWI will be measured by PiCCO monitoring system.

Device: PiCCO monitoring system

Interventions

The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).

patients with sepsis related ALI/ARDS.

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Septic patients receiving endotracheal mechanical ventilation for hypoxemic acute respiratory failure were eligible if the following criteria were met for no more than 48 hours before enrollment: ratio of partial pressure of arterial oxygen over fraction of inspired oxygen (PaO2:FIO2) no greater than 300 mm Hg at time of enrollment, recent appearance of bilateral pulmonary infiltrates consistent with edema, and no clinical evidence of left atrial hypertension (pulmonary-capillary wedge pressure \_18 mm Hg, when available).

You may qualify if:

  • sepsis in ICU within 48 hours,
  • mechanical ventilator use,
  • PaO2/FiO2 \< 300,

You may not qualify if:

  • age younger than 20 years,
  • known pregnancy,
  • participation in another trial within 30 days before meeting the eligibility criteria, and
  • terminal malignancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chung Gung Memorial Hospital

Linkou, Taiwan, 333, Taiwan

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

To measure the relationship between endothelial injury (serum TM, vWF, VEGF, TIE-2 increase and imbalance of ANG-1/ANG-2) and vascular permeability and EVLWI in patients, 20ml peripheral blood will be sampling retented on day 1 and day 3 after including.

MeSH Terms

Conditions

Respiratory Distress Syndrome

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesRespiration Disorders

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending physician

Study Record Dates

First Submitted

September 23, 2012

First Posted

September 27, 2012

Study Start

July 1, 2011

Primary Completion

December 1, 2016

Study Completion

January 1, 2017

Last Updated

July 28, 2015

Record last verified: 2012-09

Locations